INS and type 1 diabetes mellitus: The Chinese 2021 guideline for the diagnosis and management of type I diabetes suggests that SGLT2 inhibitors may be considered in T1DM with informed consent and a BMI ≥25 kg/m2 with poor insulin control (5).